Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes

References

• Fox KM, Gerber Pharmd RA, Bolinder B, et al. Prevalence of inadequate glycaemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388–95
   PubMed Web of Science ®Google Scholar
• Nichols GA, Alexander CM, Girman CJ, et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006;29:504–9
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement of multiple therapies (UKPDS 49). J Am Med Assoc 1999;281:2005–12
   Google Scholar
• Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625–31
   Google Scholar
• Campbell IW, Mariz S. β-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007;76:163–76
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000;22:1395–409
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a 12-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744–54
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093–104
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, Gaddi AV, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005;27:1383–91
   PubMed Web of Science ®Google Scholar
• Ginis AA, Karamanos B, Charalampidou E, et al. Evaluation of changes of glycaemic control and lipid parameters in patients with T2DM after one year of treatment with pioglitazone in combination with metformin or sulfonylurea in a Greek observational study [Abstract]. Diabetologia 2006;49(Suppl 1):490
   Google Scholar
• Charbonnel B, Scheen A. Combination therapy with pioglitazone and either metformin or sulfonylurea: glycemic results from PROactive [Abstract]. Diabetes 2006;55(Suppl 1):A478
   Google Scholar
• Perez A, Spanheimer R, Khan M. Glycaemic control in patients with type 2 diabetes: the effects of pioglitazone vs glyburide in a 3-year randomized double-blind trial [Abstract]. Diabetologia 2006;49(Suppl 1):490
   Google Scholar
• Derosa G, D’Angelo A, Ragonesi PD, et al. Metformin– pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375–83
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49: 1711–21
   Google Scholar
• Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001. Diabetes Care 2003;26: 1852–5
   Google Scholar
• Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995–1000
   PubMed Web of Science ®Google Scholar
• Bell DS, Ovalle F. Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. Diabetes Obes Metab 2004;6:363–6
   PubMed Web of Science ®Google Scholar
• Campbell IW. The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2006;6:207–15
   Google Scholar
• Ristic S, Collober-Maugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006;23:757–62
   PubMed Web of Science ®Google Scholar
• Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005;28:2093–9
   Google Scholar